Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Small Data

Joined: 13/10/20


Comments by Small Data
Sonos Dec 16, 2020 2:33AM ET
Today, Sonos announced that Legrand will be licensing Sonos's patents for manufacturing its NUVO multi-room wireless audio products going forward
Tcr2 Therapeutics Dec 15, 2020 11:10AM ET
price target raised to $58 from $33 at Mizuho price target raised to $45 from $35 at Piper Sandler price target raised to $65 from $46 at BMO Capital price target raised to $37 from $32 at H.C. Wainwright
Tcr2 Therapeutics Dec 15, 2020 11:03AM ET
the best paper ever)
Bristol-Myers Squibb Dec 11, 2020 7:32AM ET
Bristol Myers Squibb Announces Settlement of U.S. Patent Litigation for REVLIMID® (lenalidomide) with Cipla
Bristol-Myers Squibb Dec 11, 2020 7:29AM ET
🔥 Bristol Myers Squibb Receives Positive CHMP Opinion for Inrebic® (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis
Pfizer Dec 11, 2020 7:26AM ET
Dec 11 (Reuters) - The U.S. Food and Drug Administration said on Friday it would work rapidly toward finalization and issuance of an emergency use authorization for Pfizer Inc's COVID-19 vaccine. A panel of outside advisers to the FDA on Thursday voted overwhelmingly to endorse emergency use of the vaccine, paving the way for the agency to authorize the shot for a country that has lost more than 285,000 lives to COVID-19. The agency has also notified the U.S. Centers for Disease Control and Prevention and Operation Warp Speed so that they can execute their plans for timely vaccine distribution. (Reporting by Ankur Banerjee in Bengaluru; Editing by Saumyadeb Chakrabarty)
G1 Therapeutics Dec 08, 2020 5:54AM ET
tomorrow 25
Atara Biotherapeutics Inc Dec 07, 2020 4:26AM ET
🚀🔥Requires reading! Bayer pays Atara bio $ atra an advance of $ 60mil and potentially $ 600 mil + royalties with a percentage of future sales towards its target Mesothelin. They enter into strategic partnerships 🚀🔥 - we are waiting for the opening of 🇷🇺 our session and the US session 🇺🇸. There should be a jerk up 🚀, pumps and gaps with closure are possible.
Fastly Dec 04, 2020 2:24PM ET
100 today ,)
Fastly Dec 04, 2020 10:06AM ET
RUMORS OF FASTLY $ FSLY ABSORPTION BY CISCO $ CSCO
Block Dec 03, 2020 6:40AM ET
New target price 300$  Evercore ISI - Square $ SQ rating upgraded to Better Market from Market Average Rocket jump)
G1 Therapeutics Nov 18, 2020 12:32PM ET
G1 Therapeutics, a clinical-stage oncology company, today announced that final overall survival (OS) data from its randomized Phase 2 trial of trilaciclib in metastatic triple-negative breast cancer (mTNBC) were consistent with preliminary findings announced last year, and showed that trilaciclib significantly improved median OS for patients treated with trilaciclib in combination with a chemotherapy regimen of gemcitabine/carboplatin. These data will be presented in a Spotlight Poster Session at the 2020 San Antonio Breast Cancer Symposium (SABCS) on Wednesday, December 9. Trilaciclib is a first-in-class investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy.
G1 Therapeutics Nov 18, 2020 11:50AM ET
conference right now!
Fastly Nov 17, 2020 5:27AM ET
(NYSE: FSLY), provider of a global edge cloud platform, announced today that Chief Executive Officer Joshua Bixby and Chief Financial Officer Adriel Lares will participate in fireside chats at the following investor conferences: Needham Virtual Security, Networking, and Communications Conference on Tuesday, November 17, 2020 at 12:00 p.m. PT / 3:00 p.m. ET Credit Suisse 24th Annual Technology Conference on Monday, November 30, 2020 at 9:20 a.m. PT / 12:20 p.m. ET 2020 Wells Fargo TMT Summit on Tuesday, December 1, 2020 at 2:20 p.m. PT / 5:20 p.m. ET Webcasts of these presentations will be available on Fastly’s Investor Relations website.